Legeis Capital Announces the Appointment of Chairman of the company’s Board of Directors

NEW YORK – Legeis Capital, LLC, which provides insurance companies with efficient access to higher-returning assets, today announced the appointment of Michael Morrissey as Chairman of the company’s Board of Directors.

Morrissey is an accomplished insurance investment banker and fund manager and served as President and CEO of the International Insurance Society (IIS), the largest insurance industry association. He is a board member at Selective Insurance Group (NASDAQ: SIGI) and Protective Life Corp.

“We are pleased to have Mike lead our Board of Directors. He is a strategic business leader and accomplished director. His distinguished career of over 40 years leading global insurance firms and asset management businesses brings unique experience that will benefit Legeis Capital significantly, “ said Michael Siegel, Founder and Chief Executive Officer.

Morrissey led the IIS for more than 11 years. Under his management, the IIS became a founding supporting institution of the United Nations’ Principles for Sustainable Insurance, and the founding organization and Secretariat of the Insurance Development Forum, a public/private partnership led by the global insurance industry, the UN and the World Bank.

“Mike brings extensive insurance industry and asset management experience to our board. He will further strengthen our firm’s considerable talent and experience and we are confident in the contributions and value his leadership will bring to our company,” said Joseph Taussig, director, who has substantial expertise in building total return insurers and reinsurers where investment returns are significant enough to enhance underwriting performance.

Before joining IIS, Morrissey was Chairman, Chief Executive Officer, and Chief Investment Officer of Firemark Investments, where he invested in insurance companies worldwide. He has advised insurance company managements and regulators and served on a number of insurance company boards in North America, Europe, and Asia.

He was the global insurance industry representative on the Private Sector Taskforce on Regulatory Convergence in Financial Services, organized by the G-20. Morrissey was formerly President of Manhattan Life Insurance Company and Executive Vice President of Crum & Forster Insurance Group.

Morrissey is a member of the Board of Overseers of the St. John’s University School of Risk Management and a member of the Steering Committee of the World Economic Forum’s Mitigating Risk in the Innovation Economy initiative. He is an insurance working group member of the National Bureau of Economic Research, a special advisor to the Asia Pacific Financial Forum, and a member of the Board of Governors of the Asia Pacific Risk & Insurance Association

Morrissey holds a B.A. from Boston College and an M.B.A. from Dartmouth College and he graduated from the Harvard Business School’s Corporate Finance Management Program. Morrissey is also a CFA charterholder and former President of the Association of Insurance and Financial Analysts.

Sapreme Appoints Björn Cochlovius as Chairman of its Board of Directors

SAPREME Technologies
SAPREME Technologies

UTRECHT, the Netherlands – Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced the establishment of its independent Board of Directors by the appointment of Björn Cochlovius, Ph.D., as Chairman of the Board, effective immediately.

“I have observed the rapid evolvement of the Company and am impressed by how far the team has come to date. I look forward to supporting the accelerated development of Sapreme’s promising technology with vast potential.”

“Björn is a pharma industry veteran with both a deep understanding of oncology research and antibody engineering as well as a strong track record of creating value by leading and executing business transactions. Björn’s appointment is particularly timely as his extensive knowledge will aid the advancement of our technology platform through late preclinical development. He will be key in advising the Company in ongoing interactions with potential partners and identifying strategic opportunities that will further validate our approach,” stated Guy Hermans, Chief Executive Officer of Sapreme.

“Sapreme is developing a unique technology that has the potential to be applied to both antibody-conjugated toxins and oligonucleotide therapeutics,” stated Björn Cochlovius, Chairman of Sapreme’s Board of Directors. “I have observed the rapid evolvement of the Company and am impressed by how far the team has come to date. I look forward to supporting the accelerated development of Sapreme’s promising technology with vast potential.”

Dr. Cochlovius brings over two decades of drug discovery, clinical development, commercial and business development experience from the biotechnology and pharmaceutical industries. He currently serves as Chairman of the Board at Isogenica, an antibody discovery biotechnology company specialized in single-domain antibody therapeutics. Additionally, Dr. Cochlovius is Acting Chairman at Karolinska Development, the investment arm of the Karolinska Institute in Stockholm and Associate Professor Immunology at the Reprecht-Karls Universität Heidelberg. Earlier in his career, he held various senior research and development positions, as well as business development and strategic positions at Abbvie Inc., Otsuka, Roche AG, Affitech AS, and others. Dr. Cochlovius began his career developing diabodies and tandem diabodies, or fully recombinant bispecific antibodies, and holds a PhD in Immunology and Oncology from the Universität des Saarlandes.

About Sapreme

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.

Contact Information

For further inquiries
Guy Hermans, CEO
+31 30 760 09 76
hermans@sapreme-technologies.com

For Media Inquiries
Trophic Communications
Eva Mulder or Valeria Fisher
+49 89 238 877 30
sapreme@trophic.eu